Strong intellectual property protection welcomed by Canadians

17 September 2012

More than three-quarters of Canadian citizens agree the country needs better or the same protection of intellectual property (IP) as its major trading partners, say figures from a Nanos Research survey conducted last week.

When asked whether Canada should have more, the same or less protection for IP as our major trading partners, more than 76% agreed Canada's IP regime should be at least the same or stronger.

"There is a significant majority of Canadians who expect a level of intellectual property protection that is equivalent or even greater than that of our key western trading partners like the United States or Europe," says Nik Nanos, president and chief executive of Nanos Research, adding: "It is also important to note that a very small minority, only 12.4%, of Canadians think we need less intellectual property protection. It is a clear signal that Canadians assign a significant level of value to intellectual property."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical